United States · Platforms & data · MarketBeat

Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029

Published by MarketBeat · United States 1 h ago

Eikon Therapeutics (NASDAQ:EIKN) expects an interim analysis of its lead melanoma study in the first half of 2027 and estimates that definitive data from that trial and a lung…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Franklin (BEN) Q4 2026 Earnings Call Transcript

Investing.com

Haiti PM says gang leader Mathias Saintil dead

MarketWatch

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

CNBC

Nasdaq drops into correction territory — here’s what typically happens next

Yahoo Finance

Strawberry Fields (STRW) Q3 2026 Earnings Call Transcript

TheStreet